159 related articles for article (PubMed ID: 25182689)
1. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
[TBL] [Abstract][Full Text] [Related]
2. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
[TBL] [Abstract][Full Text] [Related]
3. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
4. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and prognostic analysis of 75 primary myelofibrosis patients].
Yu Q; Xu L; Gao X; Xu W; Yan H; Wu W; Li J; Shen Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):922-5. PubMed ID: 25339331
[TBL] [Abstract][Full Text] [Related]
8. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
Pardanani A; Lasho TL; Finke CM; Rajkumar SV; Singh PP; Ketterling RP; Hanson CA; Katzmann JA; Tefferi A
J Clin Oncol; 2012 Apr; 30(10):1087-94. PubMed ID: 22331938
[TBL] [Abstract][Full Text] [Related]
9. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
10. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
[TBL] [Abstract][Full Text] [Related]
11. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
[TBL] [Abstract][Full Text] [Related]
12. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
13. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F; Maffioli M; Cervantes F; Vannucchi AM; Morra E; Barbui T; Caramazza D; Pieri L; Rumi E; Gisslinger H; Knoops L; Kiladjian JJ; Mora B; Hollaender N; Pascutto C; Harrison C; Cazzola M
Blood; 2014 Mar; 123(12):1833-5. PubMed ID: 24443442
[TBL] [Abstract][Full Text] [Related]
14. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
15. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
16. Pruritus in primary myelofibrosis: clinical and laboratory correlates.
Vaa BE; Wolanskyj AP; Roeker L; Pardanani A; Lasho TL; Finke CM; Tefferi A
Am J Hematol; 2012 Feb; 87(2):136-8. PubMed ID: 22081434
[TBL] [Abstract][Full Text] [Related]
17. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
20. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A
Blood; 2010 Mar; 115(9):1703-8. PubMed ID: 20008785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
